A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)
Public ClinicalTrials.gov record NCT03556007. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Double-blind, Randomized, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous NKTR-358 in Patients With Systemic Lupus Erythematosus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in participants with SLE. The study will last about 79 days for each participant.
Study identification
- NCT ID
- NCT03556007
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2018 (Actual)
- Primary completion
- Aug 29, 2019 (Actual)
- Completion
- Aug 29, 2019 (Actual)
- Last update posted
- Nov 18, 2023
2018 – 2019
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site - Anniston | Anniston | Alabama | 36207 | — |
| Investigator Site - La Jolla | La Jolla | California | 92037 | — |
| Investigator Site - Clearwater | Clearwater | Florida | 33765 | — |
| Investigator Site - Orlando | Orlando | Florida | 32806 | — |
| Investigator Site-Tampa | Tampa | Florida | 33603 | — |
| Investigator Site - Great Neck | Great Neck | New York | 11021 | — |
| Investigator Site- Wilmington | Wilmington | North Carolina | 28401 | — |
| Investigator Site - Middleburg Heights | Middleburg Heights | Ohio | 44130 | — |
| Investigator Site - Duncansville | Duncansville | Pennsylvania | 16635 | — |
| Investigator Site - Jackson | Jackson | Tennessee | 38305 | — |
| Investigator Site - Memphis | Memphis | Tennessee | 38119 | — |
| Investigator Site - Austin | Austin | Texas | 78745 | — |
| Investigator Site - Dallas | Dallas | Texas | 75231 | — |
| Investigator Site - Mesquite | Mesquite | Texas | 75150 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03556007, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2023 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03556007 live on ClinicalTrials.gov.